India’s pharmaceutical sector has delivered several robust IPO performances over the past few years. Pharma companies consistently remain on investors’ radar due to the continuously rising demand for healthcare and medicines. Currently, the Goldline Pharmaceutical IPO in the SME segment is also generating significant buzz, as the company is expanding its healthcare operations across multiple states and is demonstrating strong financial growth.
About Goldline Pharmaceutical Business
Goldline Pharmaceutical operates in the healthcare and pharmaceutical distribution sector. The company provides medicines and healthcare products in different therapeutic segments. A company that sells products under the “Goldline” brand in India.
The company’s major business operations include:
- Cardiology medicines
- Diabetes care products
- Wellness products
- Critical care medicines
- Pediatric healthcare
- Orthopedic medicines
- Gastroenterology segment products
The company also has multiple branded divisions:
- Goldline Pharma
- Goldline Cardinal
- Goldline Ayushman
- Goldline In Life
- Goldline Wellness
Goldline Pharmaceutical IPO Price & Investment Details
| Particulars | Details |
|---|---|
| Face Value | ₹10 per share |
| Price Band | ₹41 to ₹43 per share |
| Issue Size | ₹11.61 Crore |
| Fresh Issue | 27.00 Lakh Shares |
| Lot Size | 3,000 Shares |
| Minimum Investment | ₹1,29,000 |
| Lead Manager | Jawa Capital Services Pvt Ltd |
| Market Maker | Rikhav Securities Ltd |
| Sector | Pharmaceutical |
Goldline Pharmaceutical IPO Important Dates
| Particulars | Details |
|---|---|
| IPO Open Date | 12 May 2026 |
| IPO Close Date | 14 May 2026 |
| Allotment Date | 15 May 2026 |
| Refund Initiation | 18 May 2026 |
| Shares Credit Date | 18 May 2026 |
| Listing Date | 19 May 2026 |
| Exchange | BSE SME |
| IPO Type | SME IPO |
| Registrar | Cameo Corporate Services Ltd |
Minimum Investment
| Category | Investment Amount |
|---|---|
| Minimum Retail Investment | ₹1,29,000 |
| HNI/NII Investment | Above ₹2,58,000 |
Goldline Pharmaceutical Financial Report
| Financial Year | Revenue | Profit After Tax (PAT) |
|---|---|---|
| FY2024 | ₹23.57 Crore | ₹1.80 Crore |
| FY2025 | ₹28.06 Crore | ₹2.83 Crore |
Financial Highlights
- In FY2025, the company witnessed growth in both revenue and profit.
- Revenue increased by approximately ₹4.49 crore compared to FY2024.
- A strong improvement was also observed in Profit After Tax, indicating business expansion and operational growth.
Goldline Pharmaceutical IPO “Pros”
- The pharmaceutical sector demonstrates strong long-term demand.
- The company operates across multiple Indian states.
- Revenue and profit growth appear positive.
- There is potential for expansion within the healthcare and wellness segments.
- Business diversification is achieved through multiple branded divisions.
Goldline Pharmaceutical IPO “Cons”
- SME IPOs tend to exhibit higher volatility.
- Liquidity may be low following the listing.
- The minimum investment amount is quite high.
- Competition within the pharmaceutical sector is intense.
- Due to the small issue size, the associated risk may be comparatively higher.
Corporate Office Address
Goldline Pharmaceutical Private Limited
Plot No. 103, F1 Leela Apartment,
Shilpa Society, Near Shanidham,
Sapthagiri, Nagpur – 440015
Goldline Pharmaceutical Contact Details
- Phone: 7122866666, 9561132666
- Email:info@goldlinepharma.in
Conclusion
The Goldline Pharmaceutical IPO is considered a promising pharmaceutical issue within the SME segment. The company’s multi-state presence and exposure to the healthcare sector could serve as positive factors for investors. However, given that it is an SME IPO, the associated risks and volatility should not be overlooked. Long-term investors should make their decisions after carefully considering the company’s financials, valuation, and business expansion plans.
Disclaimer
This article is for educational purposes only. IPO investments are subject to market risks. Please consult your financial advisor before investing in any IPO.
